Evidence map›Paper›PMID 40612435›Full record

ReviewFrontiers in endocrinology2025

Harnessing beta-cell replication: advancing molecular insights to regenerative therapies in diabetes.

Rupangi C Vasavada, Sangeeta Dhawan

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rupangi C VasavadaDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA, United States.
Sangeeta DhawanDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA, United States.

Funding

Regulation of beta-cell homeostasis by DNA methylation and hydroxymethylation.R01DK120523 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DHAWAN, SANGEETA · 2019 to 2023
$2.2M
NIDDK NIH HHS R01 DK120523
6 · The paper itself

Abstract

Diminished functional beta-cell mass is a key pathogenic mechanism underlying both type 1 and type 2 diabetes (T1D and T2D), precipitated by the progressive impairment of insulin secretion, loss of cellular identity, and ultimately, beta-cell death. The replenishment of beta-cell deficit through the transplantation of pancreatic islets from cadaveric donors or beta-cells derived from human embryonic stem cells has shown transformative therapeutic potential. However, the regeneration of functional beta-cell mass

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Insulin-Secreting CellsRegenerationRegenerative MedicineAnimalsCell DifferentiationHumansIslets of Langerhans Transplantationbeta cellsdiabetesproliferationregenerationreplicationtherapeutics

Identifiers

PMID40612435
PMCPMC12221927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.